The PAZOREAL study: A non-interventional study to assess efficacy and safety of Pazopanib and everolimus in a real life settin; reflecting a changing mRCC treatment landscape.

Goebell, P.-J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Welslau, M., 2016.

Oncol Res Treat 39 (suppl.3)(P883), 267. doi:10.1159/000449050

Studie: PAZOREAL; Indikation: Nierenzellkarzinom; Jahr: 2016; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com